RxDoctor Payments Data

Derek Cunningham

Optometrist · Austin, TXNPI 1265407084

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $582,247 of the $940,294 with a category attached, or 61.9%. 31 manufacturers reported payments, led by Sun Pharmaceutical Industries Inc. at 26.0% of the total. Among optometrist clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$940,294in general payments, 2019–2025

Across 1,483 payments — averaging $634.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$244K
  • Bausch & Lomb Americas Inc.$239K
  • Sight Sciences, Inc.$145K
  • Shire North American Group Inc$56K
  • Novartis$56K
  • Alcon$49K
  • plus $152K from 25 others

What the payments were for

  • Consulting fees$244,00926%
  • Speaking & faculty fees$582,24762%
  • Travel & lodging$84,9079%
  • Food & beverage$28,7573%
  • Gifts$3730%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$940,294 in reported general payments places this provider in the 95th percentile of 4,315 optometrist providers in Texas.

See all optometrist providers in Texas

Medicare billing

Part B allowed, 2024
$134,531
Medicare patients
423
Services billed
886

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast528$733,401
RestasisCyclosporine84$106,159
MieboPerfluorohexyloctane/Pf100$84,322
CequaCyclosporine60$55,783
Lotemax SmLoteprednol Etabonate137$34,382
VevyeCyclosporine37$28,840
VyzultaLatanoprostene Bunod36$15,564
EysuvisLoteprednol Etabonate28$13,334
ZyletTobramycin/Lotepred Etab33$11,513
ProlensaBromfenac Sodium28$10,215
TyrvayaVarenicline Tartrate13$9,047
SimbrinzaBrinzolamide/Brimonidine Tart22$5,629
CombiganBrimonidine Tartrate/Timolol13$3,360
Brimonidine Tartrate15$2,861
Alphagan PBrimonidine Tartrate13$2,708

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$238,545$833,287664 claims
AbbVieRestasis, Combigan, Alphagan P$248$112,227110 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Zylet, Prolensa$35,917$56,110198 claims
Sun Pharmaceutical Industries Inc.Cequa$244,034$55,78360 claims
Harrow Eye, LLCVevye$7,371$28,84037 claims
Kala Pharmaceuticals, Inc.Eysuvis$42,994$13,33428 claims
Oyster Point Pharma, Inc.Tyrvaya$9,628$9,04713 claims
AlconSimbrinza$48,558$5,62922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,315 optometrist providers in Texas.

Other optometrist in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →